[go: up one dir, main page]

MX2024000118A - Anticuerpos monoclonales de adn dirigidos al virus de la influenza. - Google Patents

Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Info

Publication number
MX2024000118A
MX2024000118A MX2024000118A MX2024000118A MX2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A
Authority
MX
Mexico
Prior art keywords
influenza virus
antibodies directed
dna antibodies
monoclonal dna
monoclonal
Prior art date
Application number
MX2024000118A
Other languages
English (en)
Inventor
David B Weiner
Jian Yan
Sarah Elliott
Ami Patel
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2024000118A publication Critical patent/MX2024000118A/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe en la presente una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo sintético anti-influenza-hemaglutinina; la descripción también proporciona un método para prevenir y/o tratar la influenza en un sujeto utilizando dicha composición y método de generación.
MX2024000118A 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza. MX2024000118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17

Publications (1)

Publication Number Publication Date
MX2024000118A true MX2024000118A (es) 2024-01-22

Family

ID=60203613

Family Applications (8)

Application Number Title Priority Date Filing Date
MX2018013521A MX2018013521A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024000118A MX2024000118A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006292A MX2024006292A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006293A MX2024006293A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006290A MX2024006290A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006295A MX2024006295A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006289A MX2024006289A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006291A MX2024006291A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013521A MX2018013521A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Family Applications After (6)

Application Number Title Priority Date Filing Date
MX2024006292A MX2024006292A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006293A MX2024006293A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006290A MX2024006290A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006295A MX2024006295A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006289A MX2024006289A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006291A MX2024006291A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Country Status (11)

Country Link
US (2) US11851477B2 (es)
EP (1) EP3452504A4 (es)
JP (3) JP7506869B2 (es)
KR (4) KR20240155978A (es)
CN (2) CN110325546B (es)
AU (2) AU2017261305B2 (es)
BR (1) BR112018072708A2 (es)
CA (1) CA3023093A1 (es)
MX (8) MX2018013521A (es)
SG (2) SG10202011021XA (es)
WO (1) WO2017192946A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240155978A (ko) * 2016-05-05 2024-10-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
AU2020323601A1 (en) * 2019-07-31 2022-03-03 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
WO2021050986A1 (en) * 2019-09-11 2021-03-18 Modernatx, Inc. Lnp-formulated mrna therapeutics and use thereof for treating human subjects
CA3237090A1 (en) * 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2025226722A1 (en) * 2024-04-22 2025-10-30 The Wistar Institute Of Anatomy And Biology Dna antibody and immunogen constructs for use in methods of treating and preventing influenza

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
CN100494370C (zh) * 2006-05-26 2009-06-03 神州细胞工程有限公司 一种优化的单克隆抗体
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
JP5780762B2 (ja) * 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
EP2483307A1 (en) * 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
LT3418300T (lt) * 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 Ｂ型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
US10087240B2 (en) * 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
CA2969214A1 (en) * 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
EP3432918A4 (en) * 2016-03-21 2020-02-12 David B. Weiner DNA ANTIBODY CONSTRUCTS AND METHOD FOR USE THEREOF
KR20240155978A (ko) * 2016-05-05 2024-10-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체

Also Published As

Publication number Publication date
AU2024203297A1 (en) 2024-06-13
KR20190035614A (ko) 2019-04-03
MX2024006291A (es) 2024-08-26
WO2017192946A1 (en) 2017-11-09
EP3452504A4 (en) 2020-07-29
EP3452504A1 (en) 2019-03-13
AU2017261305A1 (en) 2018-12-20
WO2017192946A8 (en) 2018-12-27
MX2024006293A (es) 2024-08-26
KR20240155978A (ko) 2024-10-29
CN118109478A (zh) 2024-05-31
CA3023093A1 (en) 2017-11-09
KR102375324B1 (ko) 2022-03-18
AU2017261305A8 (en) 2019-08-08
CN110325546B (zh) 2024-03-19
US20190135899A1 (en) 2019-05-09
AU2017261305B2 (en) 2024-06-13
US11851477B2 (en) 2023-12-26
MX2024006289A (es) 2024-08-26
CN110325546A (zh) 2019-10-11
KR20230125851A (ko) 2023-08-29
MX2024006295A (es) 2024-08-26
JP2025081330A (ja) 2025-05-27
SG10202011021XA (en) 2020-12-30
BR112018072708A2 (pt) 2019-02-19
JP2022116034A (ja) 2022-08-09
US20240150442A1 (en) 2024-05-09
MX2024006290A (es) 2024-08-26
JP7506869B2 (ja) 2024-06-27
MX2018013521A (es) 2019-06-10
JP2019521702A (ja) 2019-08-08
KR20220035288A (ko) 2022-03-21
SG11201809783RA (en) 2018-12-28
MX2024006292A (es) 2024-08-26

Similar Documents

Publication Publication Date Title
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2024000125A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
AR103488A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
AR100367A1 (es) Anticuerpos biespecíficos químicamente bloqueados
AR118763A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
AR087749A1 (es) Anticuerpos anti-xcr1 humano
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
EA201892523A1 (ru) Днк-моноклональные антитела, нацеленные на вирус гриппа
MX2020008062A (es) Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof
EA201892124A1 (ru) Днк-конструкции антител и способы их применения
EA202091829A1 (ru) Конструкты антител на основе нуклеиновой кислоты для использования против респираторного синцитиального вируса
AR105762A1 (es) Anticuerpos anti-ccl-1 y métodos de uso